Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellmann, Matthew D., Nathanson, Tavi, Rizvi, Hira, Creelan, Benjamin C., Sanchez-Vega, Francisco, Ahuja, Arun, Ni, Ai, Novik, Jacki B., Mangarin, Levi M.B., Abu-Akeel, Mohsen, Liu, Cailian, Sauter, Jennifer L., Rekhtman, Natasha, Chang, Eliza, Callahan, Margaret K., Chaft, Jamie E., Voss, Martin H., Tenet, Megan, Li, Xue-Mei, Covello, Kelly, Renninger, Andrea, Vitazka, Patrik, Geese, William J., Borghaei, Hossein, Rudin, Charles M., Antonia, Scott J., Swanton, Charles, Hammerbacher, Jeff, Merghoub, Taha, McGranahan, Nicholas, Snyder, Alexandra, Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836/
https://www.ncbi.nlm.nih.gov/pubmed/29657128
http://dx.doi.org/10.1016/j.ccell.2018.03.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836/
https://www.ncbi.nlm.nih.gov/pubmed/29657128
http://dx.doi.org/10.1016/j.ccell.2018.03.018

Ejemplares similares